[{"data":1,"prerenderedAt":184},["ShallowReactive",2],{"drug-desvenlafaxine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":12,"synonyms":16,"formulations":19,"regimens":50,"contraindications":74,"warnings":84,"renal":99,"monitoring":108,"interactions":109,"review":110,"examples":113,"atc":119,"iran":121,"links":128,"populations":145,"usApproval":179},"desvenlafaxine",1,{"fa":7,"en":8},"دسونلافاکسین","Desvenlafaxine","nervous-system",{"fa":11,"en":11},"SNRI",[13],{"name":14,"market":15},"Pristiq","US",[17,18,7],"pristiq","پریستیک",[20,34,42],{"id":21,"form":22,"route":23,"label":24,"concentration":25,"markets":29,"refs":30},"er-25","tablet","oral","25 mg extended-release tablet (swallow whole)",{"amount":26,"unit":27,"perUnit":22,"scored":28},25,"mg",false,[15],[31],{"source":32,"section":33},"fda-desvenlafaxine","3",{"id":35,"form":22,"route":23,"label":36,"concentration":37,"markets":39,"refs":40},"er-50","50 mg extended-release tablet (swallow whole)",{"amount":38,"unit":27,"perUnit":22,"scored":28},50,[15],[41],{"source":32,"section":33},{"id":43,"form":22,"route":23,"label":44,"concentration":45,"markets":47,"refs":48},"er-100","100 mg extended-release tablet (swallow whole)",{"amount":46,"unit":27,"perUnit":22,"scored":28},100,[15],[49],{"source":32,"section":33},[51],{"id":52,"disease":52,"label":53,"population":56,"type":60,"unit":27,"dose":61,"refs":62,"notes":65},"mdd",{"fa":54,"en":55},"افسردگی اساسی — ۵۰ mg یک بار در روز","Major depressive disorder — 50 mg once daily",{"minAge":57},{"value":58,"unit":59},18,"year","fixed",{"perDose":38,"dosesPerDay":5},[63],{"source":32,"section":64},"2.1",[66],{"text":67,"refs":70},{"fa":68,"en":69},"۵۰ mg هم دوز شروع و هم درمانی است؛ دوز بالاتر سود بیشتری نشان نداده. قطع تدریجی (۲۵ mg برای کاهش تدریجی).","50 mg is both the starting and therapeutic dose; higher doses showed no extra benefit. Taper on stopping (25 mg is for tapering).",[71,72],{"source":32,"section":64},{"source":32,"section":73},"2.5",[75],{"id":76,"severity":77,"text":78,"refs":81},"ci","block",{"fa":79,"en":80},"حساسیت به دسونلافاکسین یا ونلافاکسین؛ MAOI همزمان یا ظرف ۷ روز پس از قطع (یا ۱۴ روز پس از قطع MAOI)؛ شروع در بیمار تحت لاینزولید یا متیلن بلو وریدی.","Hypersensitivity to desvenlafaxine or venlafaxine; MAOIs concurrently or within 7 days of stopping (or 14 days after stopping an MAOI); starting in a patient on linezolid or IV methylene blue.",[82],{"source":32,"section":83},"4",[85,92],{"text":86,"refs":89},{"fa":87,"en":88},"هشدار جعبه‌ای: افزایش افکار و رفتار خودکشی در کودکان، نوجوانان و جوانان.","Boxed warning: increased suicidal thoughts and behaviour in children, adolescents and young adults.",[90],{"source":32,"section":91},"Boxed Warning",{"text":93,"refs":96},{"fa":94,"en":95},"سندرم سروتونین؛ افزایش فشار خون (پایش)؛ خونریزی با NSAID\u002Fآسپرین\u002Fضدانعقاد.","Serotonin syndrome; raised blood pressure (monitor); bleeding with NSAIDs\u002Faspirin\u002Fanticoagulants.",[97],{"source":32,"section":98},"5",[100],{"egfrBelow":38,"severity":101,"text":102,"refs":105},"warn",{"fa":103,"en":104},"ClCr ۳۰ تا ۵۰: حداکثر ۵۰ mg\u002Fروز؛ ClCr زیر ۳۰ یا ESRD: ۲۵ mg روزانه یا ۵۰ mg یک روز در میان.","CrCl 30–50: max 50 mg\u002Fday; CrCl \u003C30 or ESRD: 25 mg daily or 50 mg every other day.",[106],{"source":32,"section":107},"2.2",[],[],{"status":111,"reviewer":112,"date":112},"unverified",null,[114],{"regimen":52,"formulation":35,"input":115,"expect":118},{"ageYears":116,"weightKg":117},40,70,{"perDose":38,"tabletsPerDoseRounded":5},[120],"N06AX23",{"status":122,"refs":123},"not-found",[124],{"source":125,"section":126,"url":127},"darooyab-generic","G-4910\u002FDesvenlafaxine","https:\u002F\u002Fwww.darooyab.ir\u002FG-4910\u002FDesvenlafaxine",[129,133,137,140,143],{"kind":130,"url":131,"label":132},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=204028","ANDA204028",{"kind":134,"url":135,"label":136},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=ff837eb1-24c3-4c63-9b4b-c6b5935a9b47","FDA Desvenlafaxine",{"kind":138,"url":139,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa608022.html",{"kind":141,"url":142,"label":120},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N06AX23",{"kind":144,"url":127,"label":8},"darooyab",{"pregnancy":146,"lactation":155,"pediatric":163,"geriatric":171},{"level":147,"text":148,"quote":151,"refs":152},"caution",{"fa":149,"en":150},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Based on data from published observational studies, exposure to SNRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage [see Warnings and Precautions (5.4) and Clinical Considerations].",[153],{"source":32,"section":154},"8.1",{"level":147,"text":156,"quote":159,"refs":160},{"fa":157,"en":158},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary Available limited data from published literature show low levels of desvenlafaxine in human milk, and have not shown adverse reactions in breastfed infants (see Data) .",[161],{"source":32,"section":162},"8.2",{"level":164,"text":165,"quote":168,"refs":169},"avoid",{"fa":166,"en":167},"هشدار جعبه‌ای برچسب درباره کودکان.","Boxed warning in the label about children.","Desvenlafaxine extended-release tablets are not approved for use in pediatric patients [see Use in Specific Populations (8.4) ] .",[170],{"source":32,"section":91},{"level":147,"text":172,"quote":175,"refs":176},{"fa":173,"en":174},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","… ly significant hyponatremia in elderly patients, who may be at greater risk for this adverse event [see Warnings and Precautions (5.9) ] .",[177],{"source":32,"section":178},"8.5",{"kind":180,"refs":181,"id":132},"ANDA",[182],{"source":32,"section":183},"SPL approval \u002F marketing category",1792115176370]